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In Brief
Pumilio1 is an RNA-binding protein that
binds Ataxin1 mRNA and regulates its
stability. Haploinsufficiency of Pumilio1
results in an increase in Ataxin1 levels,
leading to progressive motor dysfunction
and degeneration of Purkinje cells,
features typical of spinocerebellar ataxia
type 1. These data suggest that either
haploinsufficiency of PUMILIO1 or
duplication of ATAXIN1 could contribute
to neurodegeneration in humans.
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Spinocerebellar ataxia type 1 (SCA1) is a paradig-
matic neurodegenerative proteinopathy, in which
amutant protein (in this case, ATAXIN1) accumulates
in neurons and exerts toxicity; in SCA1, this process
causes progressive deterioration of motor coordina-
tion. Seeking to understand how post-translational
modification of ATAXIN1 levels influences disease,
we discovered that the RNA-binding protein
PUMILIO1 (PUM1) not only directly regulates
ATAXIN1 but also plays an unexpectedly important
role in neuronal function. Loss of Pum1 caused
progressive motor dysfunction and SCA1-like neuro-
degeneration with motor impairment, primarily
by increasing Ataxin1 levels. Breeding Pum1+/
mice toSCA1mice (Atxn1154Q/+) exacerbateddisease
progression, whereas breeding them to Atxn1+/
mice normalized Ataxin1 levels and largely rescued
the Pum1+/ phenotype. Thus, both increased wild-
type ATAXIN1 levels and PUM1 haploinsufficiency
could contribute to human neurodegeneration.
These results demonstrate the importance of study-
ing post-transcriptional regulation of disease-driving
proteins to reveal factors underlying neurodegene-
rative disease.INTRODUCTION
Misfolded proteins underlie the pathogenesis of a number of
neurodegenerative conditions, collectively known as proteino-
pathies. Alzheimer disease (AD), Parkinson disease (PD), amyo-
trophic lateral sclerosis (ALS), and polyglutamine diseases such
as Huntington disease all fall into this category (Ross and Poirier,
2004; Soto, 2003). Despite the heterogeneity of their pathogenic
mechanisms, in each of these diseases, the misfolded protein
accumulates in neurons and exerts toxicity. Somewhat surpris-
ingly, the brain can also be sensitive to elevated levels of wild-
type (WT) protein: duplication of the amyloid precursor protein
(APP) locus causes autosomal dominant early-onset AD (Rove-
let-Lecrux et al., 2006; Rumble et al., 1989), and duplications
or triplications of a-synuclein (SNCA) are associated with familial
PD (Chartier-Harlin et al., 2004; Iba´n˜ez et al., 2004; Singleton
et al., 2003). Along similar lines, it has been shown recently
that leucine-rich repeat kinase 2 (LRRK2) mutations, the most
common cause of inherited PD, increase overall protein synthe-
sis inDrosophila, and that reduction in dLRRK levels is protective
(Martin et al., 2014).
Spinocerebellar ataxia type 1 (SCA1) is paradigmatic of the
subgroup of polyglutamine (polyQ) proteinopathies caused by
expansion of an unstable CAG repeat in the coding region of
the relevant disease gene, in this case ATAXIN1 (ATXN1)
(Orr et al., 1993). The onset of SCA1 is usually in mid-life, when
motor coordination begins to deteriorate because of cerebellar
degeneration; patients eventually die of bulbar dysfunction thatCell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc. 1087
renders them unable to clear their airway (Zoghbi and Orr, 2009).
There is clear evidence that the expanded polyQ tract stabilizes
ATXN1 and causes it to resist being cleared by the ubiquitin-
proteasome pathway, in effect increasing its abundance in
neurons (Cummings et al., 1999). Notably, the severity of neuro-
degeneration in fly and mouse models of SCA1 correlates
directly with levels of mutant ATXN1 protein (Burright et al.,
1995; Fernandez-Funez et al., 2000), and massive overex-
pression of even WT ATXN1 under the Purkinje-cell-specific
promoter can produce a mild SCA1-like phenotype in mice
(Fernandez-Funez et al., 2000).
Although the artificiality of transgenic models limits their rele-
vance to the human disease, these results from SCA1 transgenic
mice, along with the evidence from familial AD and PD patients,
led us to ask whether there were post-transcriptional modifica-
tions that might increase the levels of WT ATXN1 in a more
physiologically relevant way and shed further light on the role
of protein levels in neurodegeneration. The extraordinarily long
30 UTR, approximately 7 kb in ATXN1mRNA, seemed to promise
a rich source of key brain-enriched post-transcriptional regula-
tory elements. To our surprise, we found that ATXN1 is regulated
directly by an RNA-binding protein (RBP), Pumilio1, and that a
brain-wide increase in WT Atxn1 levels of only 50%, caused
by Pum1 haploinsufficiency, is sufficient to causemarked neuro-
degeneration in mice.
RESULTS
The RBP PUMILIO1 Regulates ATAXIN1 Levels in Cells
Two types of molecules are known to modulate protein levels
by binding to the corresponding mRNA: RBPs and microRNAs
(miRNAs). RBPs bind to specific sequence motifs or secondary
structures in mRNAs and regulate multiple steps in RNA
metabolism, such as splicing, nucleus-cytoplasm transport,
and translation (Lukong et al., 2008). On the other hand, miRNAs
are small non-coding RNAs that control various developmental
and physiological processes by suppressing the expression
of their target genes via binding of a short (6–8 nucleotide) com-
plementary seed region in the 30 UTRs of mRNAs (Bartel, 2009).
We first scanned the 7 kb-long ATXN1 30 UTR for potential
binding sites for miRNAs by using the TargetScan (Friedman
et al., 2009), CoMeTa (Gennarino et al., 2012), and HOCTARdb
(Gennarino et al., 2011) prediction tools. As expected, scanning
identified dozens of potential miRNA-binding sites (data not
shown). Because RNA folding mediates miRNA-RNA interac-
tions by masking or exposing specific binding-site sequences,
we analyzed the secondary structure of the ATXN1-30 UTR
(Wan et al., 2014) to prioritize the best candidate ATXN1-modu-
lating miRNAs. This revealed a complicated secondary structure
that masks the binding sites for almost all of the putative miRNAs
that might target the ATXN1-30 UTR (Figure S1). For miRNAs
to act on ATXN1 mRNA, they would likely require the help of
RBPs to unfold such a structure.
Scan analysis of the human ATXN1-30 UTR revealed three
putative Pumilio1 (PUM1) binding motifs (Wang et al., 2002) at
positions 682, 2812, and 5275 from the beginning of the UTR
(Figure 1A). The RBP PUM1 regulates its target genes by
inducing a conformational switch in the 30 UTR that unmasks1088 Cell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc.specific miRNA-binding sites (Kedde et al., 2010; Miles et al.,
2012). Interestingly, the motif in position 5275 (Figure 1A,
red box) is highly conserved across several species and repre-
sents the canonical PUM1-binding motif (50-UGUAXAUA-30)
(Galgano et al., 2008; Wang et al., 2002). Overexpressing
PUM1 in HEK293T cells reduced ATXN1 mRNA levels,
whereas decreasing PUM1 by two different RNAi increased
ATXN1 mRNA levels (Figure 1B). In vitro overexpression of
PUM1 consistently decreased the luciferase activity of a
reporter construct expressing the full-length ATXN1-30 UTR
(Figure 1C). Mutation of each PUM1-binding motif within the
ATXN1-30 UTR revealed that only the most conserved site,
containing the canonical motif, is functional; when mutated,
it abolished the effect of PUM1 overexpression on luciferase
activity (Figure 1D).
Pum1 IsWidely Expressed inMouseBrain andRegulates
Atxn1 Levels In Vivo
To examine the endogenous expression pattern of Pum1 in
mice, we performed in situ hybridization assays (ISH) and
western blot on 3-week-old mouse brain sections. Pum1 was
expressed in all major brain regions in WT mice, almost
completely absent in the brain of null mice, and reduced in
heterozygous (Pum1+/) brains (Figure S2A). We also confirmed
that Pum1 protein is widely expressed in the brain at 5 weeks
of age (Figure S2B).
To determine whether Pum1 binds Atxn1 mRNA in vivo,
we performed an RNA cross-linking and immunoprecipitation
assay (RNA-Clip) on cerebra and cerebella from 5-week-old
WT animals, using Pum1 knockout mice (Pum1/) as negative
controls (Figure S2C). We found that Pum1 physically interacts
with the conserved binding site of the Atxn1-30 UTR in WT
mice (Figure 2A). Consistent with the finding that Pum1 nega-
tively regulates Atxn1, Pum1 heterozygous (Pum1+/) mice
showed increased levels of both Atxn1 protein (Figure 2B) and
mRNA (Figure 2C)—approximately 30% in the cerebrum and
50% in the cerebellum—and Pum1/ mice showed even
more pronounced increases (Figures 2B and 2C). These data
demonstrate that Pum1 directly regulates Atxn1 levels in the
mouse brain.
PUM1 Controls ATXN1 Levels by Affecting RNA Stability
and not through the miRNA Machinery
Several mRNA subsets contain target sites for both RBPs and
miRNAs, and cooperation between these two types of post-tran-
scriptional regulators has been described (Bhattacharyya et al.,
2006; Fabian and Sonenberg, 2012; Glorian et al., 2011; Kim
et al., 2009; Kundu et al., 2012). This may be particularly relevant
for PUM1, as studies have indicated extensive interaction be-
tween PUM1 and the miRNA regulatory system (Kedde et al.,
2010; Galgano et al., 2008).
To determine whether PUM1 regulates ATXN1 throughmiRNA
by inducing a conformational switch in its 30 UTR, we overex-
pressed PUM1 in HEK293T cells along with miR-101a, a miRNA
known to modulate ATXN1 levels (Lee et al., 2008). These condi-
tions significantly reduced levels of ATXN1 protein (Figures 3A
and S3A) and mRNA (Figure S3E), but no more than overex-
pressing miR-101a or PUM1 separately. In fact, overexpression
Figure 1. PUM1 Regulates ATXN1 Levels
via a Highly Conserved Binding Motif
(A) Schematic representation of human ATXN1-30
UTR showing three putative PUM1-binding motifs
(gray and red boxes) and their conservation in
different species. The numbers indicate positions
of PUM1 motifs in the human ATXN1-30 UTR.
(B) ATXN1 mRNA quantification by qRT-PCR
in HEK293T cells upon overexpression (left panel)
or knockdown (siPUM1-81 and -82) (right panel)
of PUM1. The destination-cloning vector (control),
scrambled siRNAs (siScr.), and cel-miR-67 were
used as negative controls. The housekeeping
gene GAPDH was used to normalize the expres-
sion of genes in all the qRT-PCR experiments.
(C) Luciferase assay in HEK293 cells over-
expressing the reporter construct harboring
the full-length ATXN1-30 UTR. In these conditions,
we overexpressed (left panel) or decreased
expression (right panel) of PUM1.
(D) Luciferase assay in HEK293T cells transfected
with single WT and mutant (MUT) putative PUM1-
binding site on the ATXN1-30 UTR. The positions
of cloned regions for each PUM1-binding motif
are indicated. The mutagenized nucleotides are
highlighted in blue.
In (C) and (D), the destination-vector (control),
RNAi scramble (siScramble), and cel-miR-67
were used as negative controls; miR-101a was
used as positive control. (RL) Renilla, (FL) Firefly
luciferase. All the experiments were performed in
triplicate (data represent mean ± SEM). p values
were calculated by Student’s t test. Statistical
significance is indicated as follows: *p < 0.05,
**p < 0.01, ***p < 0.0001. See also Figure S1.of miR-101a along with PUM1 knockdown consistently
decreased levels of ATXN1 protein (Figures 3B and S3B)
and mRNA (Figure S3F) to a degree comparable to that of
miR-101a overexpression alone. These results suggest that
PUM1 regulates ATXN1 in a miR-101a-independent fashion
but do not exclude the possibility that other miRNAs bind the
ATXN1 30 UTR. To obviate testing the effect of PUM1 on all
possible miRNAs regulating ATXN1, we knocked down the
catalytic engine of the RNA-induced silencing complex (RISC),
Argonaute-2 (AGO2), to globally inhibit miRNA binding and
retested PUM1’s ability to regulate ATXN1. We found that
PUM1 overexpression in the context of AGO2 knockdown still
reduced levels of both ATXN1 protein (Figures 3C and S3C)
and mRNA (Figure S3G). Conversely, simultaneous RNAi of
PUM1 and AGO2 increased levels of both ATXN1 protein (Fig-
ures 3D and S3D) and mRNA (Figure S3H), but no more than
silencing PUM1 alone. These data establish that PUM1 modu-
lates ATXN1 levels directly by binding its 30 UTR, without the
assistance of the miRNA machinery.
To further explore the mechanism by which PUM1 regulates
ATXN1 levels, we tested whether PUM1 influences the stability
or the translation of ATXN1 mRNA. We transfected HEK293T
with a luciferase reporter encoding an ATXN1-30 UTR harboring
either the conserved WT or mutated (Mut) PUM1-binding site.Later, we used treatment with DRB (5,6-dichloro-1-b-D-ribofur-
anosylbenzimidazole), a drug that inhibits RNA translation by
blocking RNA polymerase II in the early elongation stage, to
assess the levels of the reporter transcript. Upon the addition
of DRB (time-point zero), the relative expression of reporter tran-
scripts containing the ATXN1-30 UTR Mut binding site is consid-
erably higher than that of transcripts containing the ATXN1-30
UTR WT binding site (Figure 3E, top panel). This difference re-
mains stable over time until 8 hr after DRB addition. Remarkably,
the ATXN1-30 UTR with Mut binding site reached its half-life
after 19 hr, whereas the ATXN1-30 UTR with WT binding site
decreased linearly over time, reaching its half-life at nearly 8 hr
(Figure 3E, top panel). Given that the promoter sequences of
the ATXN1-30 UTR constructs carrying either WT or Mut binding
sites are exactly the same and that transfection of neither
construct affected PUM1 protein levels, we conclude that
PUM1 promotes degradation of ATXN1 by binding its 30 UTR
(Figures 3E, bottom panel and S3I).
To investigate physiological changes in ATXN1 mRNA, we
decided to knock down PUM1 in HEK293T cells and measure
the half-life of endogenous ATXN1mRNA at different time points
after DRB treatment. Knockdown of PUM1 (siPUM1) was
associated with a significant increase of ATXN1 mRNA from
time zero and remained upregulated up to 8 hr after translationCell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc. 1089
Figure 2. Pum1 Directly Binds the 30 UTR of Atxn1 to Regulate Its
Levels in Mouse Cerebrum and Cerebellum
(A) RNA-Clip for the conserved Pum1-binding site in mouse cerebrum and
cerebellum. PCRu and PCRd highlight the PCR fragments upstream and
downstream of the conserved Atxn1-30 UTR Pum1-binding site (BS). IP with
IgG as well Pum1 null mice were used as negative controls. Isolated RNA
from a fraction (10%) of pre-cleared lysate was used as input. The experiment
was performed in triplicate.
(B and C) Quantification of Atxn1 protein (B) and mRNA levels (C) in WT and
Pum1/ mice in cerebrum and cerebellum (n = 8 per genotype).
Data represent mean ± SEM and normalized to Gapdh. See Experimental
Procedures for more details. p values were calculated by Student’s t test;
*p < 0.05, **p < 0.01, ***p < 0.0001. See also Figure S2.
1090 Cell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc.inhibition (Figure 3F, top panel). Our calculation consistently
showed that the half-life of ATXN1 mRNA was much longer
(nearly 12 hr) after siPUM1 than after siScramble transfection
(4 hr) (Figure 3F, top panel). We confirmed PUM1 downregula-
tion by quantifying mRNA at time zero (Figure S3J) and protein
levels at different time points (Figures 3F, bottom panel and
S3K). PUM1 thus increases ATXN1 levels by directly regulating
the stability of ATXN1 mRNA.
Pum1 Mutant Mice Develop Progressive Motor
Dysfunction and Neurodegeneration
Recent studies have shown that Pum1 is an essential regulator
of spermatogenesis in mice and promotes differentiation of
embryonic stem cells (Chen et al., 2012; Leeb et al., 2014), but
its role in the mammalian nervous system has not been inves-
tigated. We therefore characterized the brain structure and
behavior of Pum1 knockout mice (Chen et al., 2012).
The Pum1 null allele tends to be transmitted with an altered
Mendelian ratio (Figure S4A). Compared to WT and Pum1+/
littermates, Pum1/ mice were significantly smaller in body
length, weight, and brain weight and size (Figures 4A and
S4B). Surprisingly, the loss of one copy of Pum1 was sufficient
to cause impaired performance on the accelerating rotarod
assay in 5-week-old mice (Figure 4B): the motor deficit had
progressed in severity by 12 weeks (Figure S4C). This motor
incoordination was even more dramatic in Pum1/ age-
matched mice (Figures 4B and S4C), which performed equally
poorly in the dowel-walking test (Figures S4D and S4E)—as
poorly, in fact, as SCA1 mice at this age in both assays (Watase
et al., 2002).
Beginning at 8 weeks of age, both Pum1+/ andPum1/mice
exhibited hind-paw claspingwhen suspended by the tail (Figures
4C and S4F), a sign of neurological dysfunction. At 10 weeks
of age, Pum1/mice displayed significantly less vertical activity
in an open-field chamber (Figure S4G) and spent less time in its
center (Figure S4H) but traveled greater distances over 30 min in
the chamber than WT (Figure 4D). Interestingly, Pum1/ mice
covered a greater distance at 18 weeks than at 10 weeks
of age (Figure S4I). Using the DigiGait assay, we found that
12-week-old Pum1/ mice had wider stances (Figure S4J),
shorter stride lengths (Figure S4K), and greater stride frequen-
cies (Figure S4L). At the same age, Pum1+/ and Pum1/
mice were poor nest builders (Figure S4M). Pum1 deficiency
thus causes progressive loss of motor coordination that appears
to be cerebellar in origin.
To uncover the defects underlying the phenotype, we per-
formed neuropathological studies. At 3 and 4 weeks of age,
there was no evidence of Purkinje cell pathology in Pum1+/ or
Pum1/ mice (Figures 4F and S4N), but by 10 weeks, Pum1
haploinsufficiency had caused loss of Purkinje cells (Figures 4E
and 4F) and dendritic arborization (Figure 4G). Both defects
were more dramatic in age-matched Pum1/ mice (Figures
4E–4G). The neuronal loss is thus a result of neurodegeneration
and not a developmental defect. Notably, progressive Purkinje
cell degeneration and motor dysfunction are hallmarks of
SCA1 in both human patients and the SCA1 knockin mouse
model (Atxn1154Q/+) (Watase et al., 2002). Because the progres-
sive defects in Pum1 mutant mice were reminiscent of those
Figure 3. PUM1Modulates the Levels ofWT
ATXN1 Independently of miRNAs
(A–D) Representative western blot (upper panel) of
protein lysates from HEK293T cells upon (A)
overexpression of both PUM1 and miR-101a; (B)
RNAi PUM1 (siPUM1) followed by overexpression
of miR-101a; (C) overexpression of PUM1 fol-
lowed by RNAi AGO2 (siAGO2); and (D) RNAi
of both PUM1 and AGO2. The negative controls
were destination-cloning vector (control), RNAi
scramble (siScramble), and cel-miR-67. All data
were normalized to a-tubulin (TUBA).
(E) mRNA half-life quantification of WT and Mut
PUM1 ATXN1-30 UTR binding sites in HEK293T
cells at different time points upon DRB treatment
(time zero). The numeric values within the panel
given the extrapolated half-life for WT and Mut
RNA, p = 3.63 1006. Firefly (FL) RNA levels were
quantified and normalized to Renilla (RL). Bottom
panel: representative western blot of PUM1 in
HEK293T cells at different time points. Data were
normalized to GAPDH.
(F) ATXN1 mRNA half-life quantification in
HEK293T cells at different time points, from
zero (DRB treatment) to 8 hr total upon RNAi of
PUM1 (siPUM1) or RNAi of scramble (siScramble)
transfection. The numeric values within the panel
given the extrapolated half-life for siPUM1 and
siScramble RNA, p = 0.012. Bottom panel: repre-
sentative western blot of PUM1 in HEK293T cells
at different time points.
Data were normalized to GAPDH mRNA (top
panel) or protein (bottom panel). All experiments
were performed in triplicate (data represent
mean ± SEM); ***p < 0.0001. See also Figure S3.observed in SCA1 mice (Watase et al., 2002), we decided to
dissect the genetic interaction between Pum1 and SCA1 mice.
Pum1 Haploinsufficiency Worsens the Phenotype
of the SCA1 Knockin Mouse
Given that Atxn1 levels were increased in Pum1+/ and in
Pum1/mice (Figure 2B), we predicted that halving the dosage
of Pum1 in the SCA1 knockin mice (Pum1+/;Atxn1154Q/+) would
exacerbate the SCA1 phenotype, and this proved to be the case.
Pum1+/;Atxn1154Q/+mice tended to be smaller than Atxn1154Q/+
and the other genotypes (lower body and brain weights, shorter
lengths, smaller brain sizes; Figures S5A and S5B) and showed
more severe motor incoordination and hind-paw clasping than
eitherAtxn1154Q/+ orPum1+/mice (Figures 5A and 5B). Notably,Cell 160, 1087–1098Pum1+/;Atxn1154Q/+mice began to show
the hind-paw clasping phenotype at
6 weeks, much earlier than age-matched
Atxn1154Q/+ mice or Pum1 single mutants
(Figure 5B). At 10 weeks of age, Pum1+/;
Atxn1154Q/+ mice traveled greater dis-
tances than WT and Atxn1154Q/+ but not
more than Pum1+/ mice (Figure S5C).
Severe kyphosis (curvature of the spine)
developed in Pum1+/;Atxn1154Q/+ mice
8 weeks earlier than SCA1 knockin mice (20 versus 28 weeks;
Figure 5C), confirming the accelerated disease course. In addi-
tion, Pum1+/;Atxn1154Q/+ mice had a significantly shorter life-
span than their Atxn1154Q/+ littermates (Figure 5D). At 12 weeks
of age, the Purkinje cell loss (Figures 5E and 5F) and arborization
defects (Figure 5G) were more dramatic in Pum1+/;Atxn1154Q/+
than with all other genotypes. These results suggest a genetic
interaction between Pum1 and Atxn1154Q .
Genetic Reduction of Atxn1 Levels Rescued the Pum1
Mutant Phenotype
To test our hypothesis that the neurological deficits of Pum1
mutant mice resulted from an increase in Atxn1 levels due to
loss of Pum1 regulation, we crossed Pum1+/ with Atxn1+/, March 12, 2015 ª2015 Elsevier Inc. 1091
Figure 4. Pum1 Mutant Mice Develop Pro-
gressive Motor Deficits and Cerebellar
Degeneration
(A) Representative pictures of 3-week-old mice.
Body size, brain weight, and brain size are
reduced in Pum1/ animals.
(B) Accelerating rotarod analysis. Mice were
trained over 4 days with four trials (t) per day. The
null mice were significantly different from WT from
day 1; by day 2, the difference between WT and
bothPum1 null and heterozygotes was statistically
significant, as was the difference between the two
mutants.
(C) Hind-paw clasping analysis in mice: a higher
score indicates a more severe phenotype (see
Figure S4F, bottom panel for scoring details). By
6 weeks of age, the null mice were statistically
different from WT; by 8 weeks, both mutant lines
were statistically significantly different from WT.
(D) Open-field test measuring the total distance
traveled of the Pum1 null mice relative to WT.
(E) Representative images of immunofluorescence
(IF) confocal microscopy in 3D depth-coding (see
Experimental Procedures). Co-staining with
a-IP3R1 and -calbindin antibodies was used to
label Purkinje cells and to reveal their arborization.
(F) Purkinje cell counts at 3, 4, and 10weeks old for
all examined genotypes.
(G) IF for Calbindin and IP3R1 were quantified and
averaged in selected rectangular cerebellar sub-
sections.
All experiments were performed in WT, Pum1+/,
and Pum1/ mice. More than 12 mice per geno-
type were considered in (A)–(D) and 6 per geno-
type in (E)–(G). Data in (A), (D), and (F) represent
mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.0001.
See also Figure S4.mice and characterized the offspring. We first confirmed
that Pum1 haploinsufficiency in the Atxn1+/ mice (Pum1+/;
Atxn1+/) at 5 weeks completely rescued the physiological pro-
tein levels of Atxn1 (Figures 6A, S6A, and S6B). At 9 weeks,
Pum1+/;Atxn1+/ mice showed no difference in body weight
(Figure S5A), length, brain weight, or brain size relative to any
other genotype (Figure S6C). Atxn1 haploinsufficiency in Pum1
mutant mice significantly mitigated the motor deficits observed
in Pum1+/ animals at 5 weeks of age (Figure 6B) and completely
rescued the hind-paw clasping (Figure 6C) and kyphosis, which
occurs at a later age of 25 weeks (Figure 6D). Interestingly,
Pum1+/;Atxn1+/ mice still traveled farther than other geno-1092 Cell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc.types and not less than Pum1+/ mice
(Figure S6D). The Purkinje cell loss (Fig-
ures 6E and 6F) and arborization defects
(Figure 6G) typical of 10-week-old
Pum1+/ mice were rescued in Pum1+/;
Atxn1+/ cerebella. This indicates that,
whatever the other pathways affected
by Pum1 deficiency, the cerebellar
degeneration, clasping, and kyphosis
are caused primarily by the influence of
Pum1 on Atxn1 levels.Lastly, we analyzed whether Pum1 overexpression could
decrease levels of mutant (polyglutamine-expanded) Atxn1
(154Q). We used AAV8 viral injection and found that, indeed,
Atxn1154Q/+ mice injected with Pum1/AAV8 showed a reduction
of both WT and mutant Atxn1 in the cerebellum, the region
most affected in SCA1, compared to controls (Atxn1154Q/+
animals injected with YFP/AAV8; Figure S6E).
DISCUSSION
Accumulation of mutant proteins in the brain has been known for
some time to underlie the progression of neurodegenerative
Figure 5. Pum1 Haploinsufficiency Exacer-
bates SCA1 Disease Progression
(A and B) A 50% reduction of Pum1 in Atxn1154Q/+
mice aggravates (A) motor incoordination on the
accelerating rotarod at 5 weeks (n = 12 per ge-
notype) and (B) hind-paw clasping when mice are
suspended by the tail (n > 12 mice per genotype).
The double mutants were statistically different
from WT beginning at week 6. See Experimental
Procedures for details.
(C) Representative picture of SCA1 and Pum1+/;
Atxn1154Q/+ mice. Pum1+/;Atxn1154Q/+ showed
severe kyphosis (curvature of the spine) at earlier
stages than their SCA1 counterparts.
(D) Haploinsufficiency of Pum1 reduces lifespan in
SCA1 background mice. p value was calculated
by long-rank test; **p < 0.01, ***p < 0.0001.
(E) Representative images of IF confocal micro-
scopy in 3D depth-coding (see Experimental
Procedures). Co-staining with a-IP3R1 and -cal-
bindin antibodies was used to label Purkinje cells
and to reveal their arborization.
(F) Purkinje cell count at 12 weeks for all examined
genotypes.
(G) IF for calbindin and IP3R1 were quantified
and averaged in selected rectangular cerebellar
subsections.
Four mice per genotype in (E), (F), and (G)
were considered. Data in (F) and (G) represent
mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.0001.
See also Figure S5.disorders such AD, PD, HD, ALS, and the spinocerebellar
ataxias. In all these diseases, the mutant proteins form insoluble
aggregates (Haass and Selkoe, 2007; Klement et al., 1998; Ross
and Poirier, 2004; Zoghbi and Orr, 2000). Considerable attention
has been devoted to the question of whether inhibiting aggre-
gate formation or promoting their dissolution would mitigate
disease (Arrasate et al., 2004; Bowman et al., 2005, 2007). The
aggregates in all these proteinopathies appear late in theCell 160, 1087–1098disease course, however, and clearly
result from processes that have been
taking place for decades. Here we asked
how protein levels affect the brain long
before aggregates form. Specifically,
we sought post-transcriptional regulatory
mechanisms that regulate WT ATXN1
levels independently of the polyglutamine
tract in order to determine whether
reducing protein levels might delay dis-
ease progression. Our studies have unex-
pectedly revealed two candidate genes
for neurodegenerative conditions in hu-
mans: WT (but upregulated) ATAXIN1
and PUMILIO1.
We began our investigation by scan-
ning the long 30 UTR of ATXN1 to identify
regulatory elements that could be used
to modulate ATXN1 levels. We found
three PUM1-binding motifs in the 30 UTR
of ATXN1, one of which is highly conserved. We used mutagen-
esis and RNA-Clip to show that Pum1 regulates Atxn1 levels by
binding directly to the highly conserved motif in its 30 UTR.
Pum1 is a member of a well-characterized family of RBPs,
known as the PUF family, which are involved in various physio-
logical processes (Spassov and Jurecic, 2003; Wickens et al.,
2002). A typical feature of these proteins is the presence of an
RNA-binding Pumilio homology domain (PUM-HD) that binds a, March 12, 2015 ª2015 Elsevier Inc. 1093
Figure 6. Atxn1 Haploinsufficiency Res-
cues Motor Deficits and Cerebellar Pathol-
ogy in Pum1+/ Mice
(A) Representative western blot showing that
haploinsufficiency of Pum1 restores physiological
Atxn1 protein levels. All experiments were per-
formed in triplicate in cerebra and cerebella
from mice at 5 weeks of age (data represent
mean ± SD). All data were normalized to Gapdh.
(B and C) Pum1+/;Atxn1+/ mice showed (B)
significant improvement in motor performance
on the accelerating rotarod (n = 12 per genotype),
(C) reduced hind-paw clasping (n > 12 per geno-
type), and (D) reduced kyphosis (curvature of the
spine; photo taken at 25 weeks).
(D–G) Purkinje cells loss (E and F) and loss
of dendritic arborization (G) were rescued in
Pum1+/;Atxn1+/ mice (n = 6 per genotype).
Staining was performed with calbindin/IP3R1
in 3D deepth-coding images. Data represent
mean ± SEM. See Experimental Procedures.
p values was calculated by Student’s t test. ns =
not significant; *p < 0.05, **p < 0.01, ***p < 0.0001.
See also Figure S6.highly conserved eight-nucleotide motif (Galgano et al., 2008).
PUF proteins regulate mRNA stability by several mechanisms
leading to mRNA instability or translational repression (Gold-
strohm et al., 2006; Suh et al., 2009). One of the most well-stud-
iedmechanisms for PUM1 activity, however, involves themiRNA
machinery: PUM1 modifies the secondary structure of the 30
UTR of its target mRNAs to allow regulation through specific1094 Cell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc.miRNAs (Fabian and Sonenberg, 2012;
Friend et al., 2012; Galgano et al., 2008;
Kedde et al., 2010; Miles et al., 2012). It
was thus surprising to find that PUM1
directly regulates ATXN1 mRNA stability
without harnessing the miRNA regulatory
system.
Equally unexpected was the discovery
of a role for Pum1 in the maintenance of
proper brain structure and neurological
function. We found Pum1 expressed
in all brain regions, but the deficits we
observed in the heterozygousmice—pro-
gressive motor incoordination, hind-paw
clasping, kyphosis, and Purkinje cell and
dendritic degeneration—were reminis-
cent of the SCA1 mouse phenotype.
The Pum1 null mice phenocopied the
SCA1 knockin mice but developed even
more severe Purkinje cell pathology,
showing significant neuronal loss after
only 2 months. We believe this is ex-
plained at least in part by constitutive
50% increase in WT Atxn1 in contrast
with the gradual nature of the accumu-
lation of polyglutamine-expanded pro-
teins. Even in the SCA1 knockin mice,the mutant protein takes time to accumulate to levels that pro-
duce symptoms. In the Pum1 mutants, however, the levels of
Atxn1 are elevated from the very beginning of life.
The dramatic exacerbation of disease progression in SCA1
knockin mice lacking a copy of Pum1 indicates a genetic inter-
action between Pumilio1 and Ataxin1, but the precocity of
disease symptoms in the double mutants could conceivably
arise through either of two mechanisms: the loss of one copy of
Pum1 directly increasing levels of mutant Atxn1, or an additive
effect ascribable to the combination of two severe mutations
(loss of Pum1 and the CAG expansion in Atxn1). Our results
argue for the former possibility. First, the defects observed in
Pum1 mutant mice were largely corrected by reducing Atxn1
levels. Second, the Pum1+/;Atxn1+/ mice were healthier
than either Pum1+/ or Atxn1+/ mice. Third, we found that
viral overexpression of Pum1 in the mouse brain reduced both
the WT and expanded [154Q] forms of the Atxn1 protein
(Figure S6E). These three facts support the notion that the
neurological deficits exhibited by the Pum1 mutant mice are
caused primarily by a rise in WT Atxn1 levels, even though other
Pum1 targets are undoubtedly affected as well. Without knowing
the full set of Pum1 targets, we cannot rule out all other path-
ways, but we were able to evaluate levels of two well-studied
PUM1 targets, E2F3 and p27, in Pum1+/as well as Pum1+/;
Atxn1+/ mice. We did not find any significant change in the
levels of these two proteins in the cerebella of either Pum1+/
or Pum1+/;Atxn1+/ mice compared to other genotypes (data
not shown).
It is well established that the severity of neurodegeneration
in SCA1 correlates with the levels of expanded (or even WT)
ATXN1 and that decreasing ATXN1 accumulation can reverse
the disease phenotypes in SCA1 models (Fernandez-Funez
et al., 2000; Park et al., 2013). It has been only relatively recently,
however, that we have understood that in some neurodegener-
ative diseases, such as AD and PD, too much of the WT protein
can produce the same phenotype as the mutant protein (Chart-
ier-Harlin et al., 2004; Iba´n˜ez et al., 2004; Rovelet-Lecrux et al.,
2006; Rumble et al., 1989; Singleton et al., 2003). Our first study
of transgenic mice overexpressing WT human ATXN1[30Q]
under the control of a Purkinje-cell-specific promoter (Pcp2-
Atxn1-(CAG)30Q) failed to reveal cerebellar pathology or ataxia
(Burright et al., 1995), but our later work monitoring the mice
throughout their lifespans revealed that Pcp2-Atxn1-(CAG)30Q
mice develop mild Purkinje cell degeneration in later life
(Fernandez-Funez et al., 2000). This suggested that only
dramatic overexpression of WT ATXN1 would be neurotoxic,
but the artificiality of the transgenic model—ATXN1 cDNA was
massively and postnatally expressed only in cerebellar Purkinje
cells and without the 30 UTR—limited its relevance for human
patients. Here we introduce the evidence that a moderate
(30%–60%) increase in the levels of endogenous WT Atxn1, ex-
pressed in the correct temporal and spatial pattern throughout
the brain and preserving all its regulatory elements, is deleterious
to neuronal function.
Atxn1 is expressed throughout the brain (Figure S2A) from very
early embryonic stages (Banfi et al., 1994, 1996; Servadio et al.,
1995). The present study suggests that mutations in PUM1
or copy-number changes in ATXN1 could cause cerebellar neu-
rodegeneration in humans by increasing the levels of ATXN1
throughout development. Variations in PUM1 or other factors
that govern ATXN1 levels could also underlie the individual
differences in SCA1 onset for the same CAG repeat length.
In conclusion, we propose that identifying molecules capable
of regulating ATXN1 levels provides insight into factors that
contribute to cerebellar degeneration. We further propose thatstudying factors that regulate the RNA stability of proteins
such as APP, TAU, or a-SYN might uncover candidate genes
as well as binding sites whose mutation could lead to AD or
PD—two diseases for which our understanding of molecular
genetic causes is still very limited. For these and the ever-
lengthening list of neurodegenerative conditions that do not fit
Mendelian categories, it may prove most fruitful to search for
factors that elevate the levels of key disease-driving proteins.
EXPERIMENTAL PROCEDURES
Bioinformatic Analysis
The ATXN1-30 UTR was downloaded from UTRdb (Grillo et al., 2010).
The ATXN1 30 UTR was scanned against CoMeTa (Gennarino et al., 2012),
HOCTARdb (Gennarino et al., 2011), and TargetScan (Friedman et al., 2009)
to identify all putative miRNAs regulating ATXN1. The secondary structure of
ATXN1-30 UTR was calculated with the Vienna RNAfold (Gruber et al., 2008)
package by using default parameters in a Minimum Free energy ‘‘MFE’’
(Zuker and Stiegler, 1981) and Boltzmann ensemble ‘‘Centroid’’ (Hofacker
and Stadler, 2006). ATXN1-30 UTR was scanned against all known RBP
motifs downloaded from the database of RBP specificities (RBPDB) (Cook
et al., 2011).
Cell Culture and Transfection
The Human embryonic kidney immortalized 293 cells (HEK293T) were grown
in DMEM (Invitrogen), supplemented with 10% of heat-inactivated fetal bovine
serum (FBS) and penicillin/streptomycin. All cells were incubated at 37C in a
humidified chamber supplemented with 5% CO2. Transfection of HEK293T
cells was performed using jetPRIME Transfection Reagent (Polyplus trans-
fection) according to the manufacturer’s protocol. Cells were transfected
with 50 pmol of either miRIDIAN Dharmacon microRNA Mimics (miR-101a
or negative control cel-miR-67) or Ambion small interfering RNA (siAGO2,
siPUM1, or scramble-siRNA control). For overexpression studies, the full
cDNA of PUM1 (4,635 nt) was amplified by Platinum Taq DNA Polymerase
High Fidelity (Invitrogen) and cloned into a mammalian expression vector
termed pcDNA3.1(+) (Invitrogen). Cells were transfected with 0.5 mg of either
pcDNA3.1(+)-PUM1 or control pcDNA3.1(+).
RNA Extraction and Quantitative Real-Time PCR
HEK293T cells were seeded in 6-well plates before transfection. After 48 hr,
cells were collected and processed for RNA extraction. Total RNA was
obtained using the miRNeasy kit (Quiagen) according to the manufacturer’s
instructions. RNA extraction from mouse cerebrum or cerebellum was
extracted from 75 mg of tissue. RNA was quantified using the NanoDrop
1000 (Thermo Fisher). Quality of RNA was assessed by gel electrophoresis.
cDNA was synthesized using Quantitect Reverse Transcription kit (Quiagen)
starting from 1 mg of DNase-treated RNA. qRT-PCR experiments were per-
formed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad
Laboratories) with PerfeCta SYBR Green FastMix, ROX (Quanta Biosciences).
Real-time PCR results were analyzed using the comparative Ct method
normalized against the housekeeping gene GAPDH (Vandesompele et al.,
2002). The range of expression levels was determined by calculating the
standard deviation of the DCt (Pfaffl, 2001).
Luciferase Assay
The full-length 30 UTR of human ATXN1 mRNA was subcloned into
psiCHECK-2 vector (Promega) by XbaI and NheI restriction enzymes
(Lee et al., 2008). The partial 30 UTR, containing binding sites 1 (582–782),
2 (2712–2912), and 3 (5175–5375), was amplified by PCR and cloned into
psiCHECK-2 vector (Promega). Mutagenesis reactions were performed using
the QuikChange XL Site-Directed Mutagenesis kit (Stratagene). Primers for
mutagenesis analysis were automatically designed by QuickChange software
(Stratagene). HEK293T cells in 24-well plates were transfected with 30 ng of
psiCHECK-2 construct plus the following: 50 pmol of siPUM1 or control
scramble-siRNA and 0.5 mg of pcDNA3.1(+)-PUM1 or control pcDNA3.1(+)Cell 160, 1087–1098, March 12, 2015 ª2015 Elsevier Inc. 1095
using Lipofectamine 2000 (Invitrogen). After 24 hr, luciferase activity was
measured using the Dual Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions.
Western Blot
HEK293T cells were seeded in 6-well plates before transfection. After 72 hr,
cells were processed for protein extraction. For mouse tissues, the entire
cerebrum and cerebellum were processed for protein extraction. Both pellet
and tissues were lysed with RIPA buffer (25 mM Tris-HCL, pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, and complete
protease inhibitor cocktail [Roche]), then placed for 15 min on ice followed
by centrifugation at 13,000 rpm at 4C for 15 min. Proteins were quantified
by Pierce BCA Protein Assay Kit (Thermo Scientific) and resolved by high-
resolution Bolt 4%–12% Bis-Tris Plus Gel (Life Technologies) according to
the manufacturer’s instruction.
RNA-CLIP
Brains from WT or Pum1 knockout mice were dissected out, and cerebella
were separated from the rest of the brains. After separation, the tissue was
triturated in 8 ml of ice-cold HBSS until cells were evenly dissociated with
no visible chunks. The cell suspension was layered on a chilled 10 cm sterile
tissue culture plate and exposed to 150 mJ/cm2 UVC (Stratagene, model UV
Stratalinker 2400) on ice. After one exposure, the cell suspension was gently
swirled and exposed again to UVC at 100 mJ/cm2. The cell suspension was
pelleted for individual immunoprecipitation (IP). Cells were lysed in lysis buffer
(50 mMTris-HCl, pH 7.4, 100 mMNaCl, 1% NP-40, 0.1% SDS, 0.5% sodium
deoxycholate, 80 U/ml RNase OUT [Invitrogen] with protease inhibitor
[Roche]). Soluble fractions were pre-cleared with protein A-sepharose beads,
rabbit control IgG (Sigma), 0.05% BSA, and 0.2 mg/ml yeast tRNA (Invitrogen).
Pre-cleared lysates were incubated with control IgG or Pum1 (5 mg) (Bethyl
Laboratories, see Antibodies) together with protein A-sepharose beads and
incubated overnight at 4Cwith gentle rotation. Next day, beads were washed
five times with lysis buffer. Beads were treated using 20 units of RNase-free
DNase (Roche) for 15 min at room temperature, followed by 50 mg proteinase
K (Roche) treatment for 30 min at 37C. Immunoprecipated RNA was isolated
using miRNeasy kit (Quiagen), and RT-PCR was performed using primers
designed to amplify Atxn1 cDNA regions upstream and downstream of the
predicted Pum1-binding site (see Primers). Isolated RNA from a fraction
(10%) of pre-cleared lysate was used as input.
RNA Stability
Total RNA fromHEK293T cells, RNA quality, cDNA synthesized, and qRT-PCR
experiments were obtained as described above in RNA Extraction and Quan-
titative Real-Time PCR. HEK293T cells were seeded in 24-well plates before
transfection for both experiments (Figures 3E and 3F). For Figure 3E, the partial
30 UTR containing the PUM1 WT or Mut binding sites 3 (5175–5375) were the
same as used for the luciferase assay (see Luciferase Assay section).
HEK293T cells were transfected with 30 ng of psiCHECK-2 vectors (Promega)
containing ATXN1-30 UTR WT or Mut binding sites using Lipofectamine
2000 (Invitrogen). After 36 hr, cells were treated with 5,6-dichloro-1-b-D-ribo-
furanosylbenzimidazole (DRB) at the final concentration of 20 mg/ml, and
total RNA for qRT-PCR analysis was collected at different time points. Firefly
data were normalized to the respective Renilla. For Figure 3F, HEK293T cells
were transfected with Ambion siRNA for PUM1 (siPUM1) or Scramble
(siScramble) at the final concentration of 40 nM. After 48 hr, cells were
collected, and the total RNA was processed for qRT-PCR. All data were
normalized toGAPDH. The housekeeping geneGAPDHwas used to compare
all the qRT-PCR values. All western blot experiments were performed as
described in the Western Blot section.SUPPLEMENTAL INFORMATION
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